

Attorney Docket No.: PU4959USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gudmundsson et al.

Serial No.: 10/530,101

Group Art Unit: 1624

Filed: April 1, 2005
Balasubramanian

Examiner: V.

For: Therapeutic Compounds Based on Pyrazolopyridine Derivatives

REQUEST FOR CERTIFICATE OF CORRECTION FOR APPLICANT'S
MISTAKE UNDER 37 CFR 1.323 AND REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR 1.322

To Commissioner for Patents

Enclosed please find a certificate of correction in connection with the above-identified patent. It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.323 and 37 CFR 1.322.

It is noted that errors appear in this patent of a clerical or typographical nature or of minor character as more fully described below and occurred in good faith and correction thereof does not involve such changes in the patent as would constitute new matter or would require re-examination. A certificate of correction is requested.

Attached hereto in duplicate is Form PTO-1050.

Please charge Deposit Account #07-1392 the sum of 100.00 as required by 37 CFR 1.20(a) and charge any additional fees which may be required by this paper, or credit any over payment, to said deposit account. A duplicate of this request is attached.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

17 April 2007
GLAXOSMITHKLINE
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone (919) 483-8222
Facsimile (919) 483-7988

DOC Code: COCIN

PTO/SB/44 (04-05)

Approved for use through 04/30/2007. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,153,863

Page 1 of 1

APPLICATION NO. : 10/530,101

ISSUE DATE : 12/26/2006

INVENTOR(S) : Gudmundsson et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Cover Page

Reads:

(56) Foreign Patent Documents

-- WO EP 0 364 204 A1 10/1989--

Should read:

(56) Foreign Patent Documents

-- EP 0 364 204 A1 10/1989--

Column 52, line 32 reads:

--N-Cyclopentyl-4-[2-isobutyl-7- (methylsulfinyl)pyrazolo--

Should read:

--N-Cyclopentyl-4-[2-isobutyl-7- (methylsulfinyl)pyrazolo--

Column 53, line 29:

--or a pharmaceutically acceptable salt, solvate or physic- --

Should read:

--or a pharmaceutically acceptable salt thereof. --

MAILING ADDRESS OF SENDER (Please do not use customer number)

GlaxoSmithKline

Corporate Intellectual Property Department

5 Moore Drive

Research Triangle Park, NC 27709

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.